Skip to main content
Clinical Trials/NCT03800420
NCT03800420TerminatedPhase 2

A Multicenter, Randomized, Double-blind, Placebo-controlled, Phase 2a Study to Evaluate the Efficacy and Safety of BBT-401-1S in Patients With Active Ulcerative Colitis

Bridge Biotherapeutics, Inc.11 sites in 1 country16 target enrollmentStarted: April 22, 2019Last updated:
Conditions
Interventions
Drugs

Trial Snapshot

Phase
Phase 2
Status
Terminated
Enrollment
16
Locations
11
Primary Endpoint
Change From Baseline in Total Mayo Score

Study Overview

Brief Summary

This is randomized, placebo-controlled, dose-escalation, multicenter, Phase 2 study to evaluate the efficacy and safety of BBT-401-1S in patients with active ulcerative colitis.

This study consists of three cohorts with 16-week treatment period per cohort that will be conducted sequentially.

Study Design

Study Type
Interventional
Allocation
Randomized
Intervention Model
Parallel
Primary Purpose
Treatment
Masking
Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)

Eligibility Criteria

Ages
18 Years to — (Adult, Older Adult)
Sex
All
Accepts Healthy Volunteers
No

Inclusion Criteria

  • Provision of signed and dated informed consent form (ICF)
  • Stated willingness to comply with all study procedures and availability for the duration of the study
  • Male or female, aged >=18 years
  • Diagnosed with active UC for at least 3 months prior to screening
  • Total Mayo score >=5 and Endoscopic sub-score >=1
  • Stable dosing regimens of oral drugs (if currently administered) as follows: 5-ASA or sulfasalazine at a stable dose for at least 4 weeks, purine analogues (azathioprine, mercaptopurine, thiopurines) or methotrexate at a stable dose for at least 12 weeks, and low-dose oral corticosteroid (up to 20 mg prednisone/day or equivalent) for at least 4 weeks prior to the first dose of study treatment. Doses of oral drugs must remain stable until the end of study treatment (with possible exception for tapering steroid dose after 8 weeks)
  • For females of reproductive potential: use of highly effective contraception for at least 1 month prior to screening and agreement to use such a method during study participation and for an additional 3 months after the last dose
  • For males of reproductive potential: use of condoms or other methods to ensure effective contraception with partner during study participation and for an additional 3 months after the last dose

Exclusion Criteria

  • Use of anti-TNF-a biologics or any other biologics for treatment of UC within 60 days prior to randomization.
  • Any rectal therapy for treatment of UC or intravenous corticosteroids within 2 weeks prior to randomization.
  • Presence of Crohn's disease, indeterminate colitis, ischemic colitis, fulminant colitis, ulcerative proctitis, or toxic mega-colon
  • Previous extensive colonic resection (subtotal or total colectomy)
  • Ileostomy, colostomy, or known fixed symptomatic stenosis of the intestine
  • Evidence of or treatment for Clostridium difficile infection or other pathogenic bowel infection within 60 days or for another intestinal pathogen within 30 days prior to randomization
  • Active infection with the HIV or Hepatitis B or C viruses
  • Clinically significant active extra-intestinal infection (e.g., pneumonia, pyelonephritis)
  • Clinically significant abnormal vital signs, physical examination or 12-lead electrocardiogram (ECG) at screening or baseline
  • Clinically significant abnormal results of liver function tests (ALT/AST, bilirubin and alkaline phosphatase) > 2X the upper limit of normal (ULN) at screening
  • Other clinically significant abnormal laboratory results at screening in the investigator's opinion
  • History of any clinically significant medical condition that, in the investigator's opinion, would preclude participation in the study
  • Pregnancy or lactation
  • Treatment with another investigational drug or other intervention within 30 days prior to screening

Arms & Interventions

BBT-401-1S

Experimental

BBT-401-1S, Oral capsule, QD

Intervention: BBT-401-1S first and then Placebo (Drug)

Placebo

Placebo Comparator

Placebo, Oral capsule, QD

Intervention: Placebo first and then BBT-401-1S (Drug)

Outcomes

Primary Outcomes

Change From Baseline in Total Mayo Score

Time Frame: Week 8

The Total Mayo score is an instrument designed to measure disease activity of ulcerative colitis, with scores ranging from 0 to 12 points. The Total Mayo score consists of 4 subscores( Stool frequency, Rectal bleeding, Findings of endoscopy, Physician global assessment), each graded from 0 to 3 with higher scores indicating more severe disease.

Secondary Outcomes

  • Change From Baseline in Partial Mayo Score(Week 8)
  • Change From Baseline in Histologic Assessment of Endoscopic Biopsy(Week 8)
  • Change From Baseline in Ulcerative Colitis Endoscopic Index of Severity (0-8)(Week 8)
  • Number and Severity of TEAEs(up to 8 weeks after the last dose)
  • Plasma Concentration of BBT- 401-1S(Day 1, Week 4, Week 8)
  • Change From Baseline in Concentration of Serum CRP(Week 8)
  • Change From Baseline in Concentration of Fecal Calprotectin(Week 8)
  • Change From Baseline in Concentration of Fecal Lactoferrin(Week 8)

Investigators

Sponsor Class
Industry
Responsible Party
Sponsor

Study Sites (11)

Loading locations...

Similar Trials

Efficacy and Safety of BBT-401-1S in... | Clinical Trial